By Colin Kellaher

 

Pfizer Inc. on Tuesday said the U.S. Food and Drug Administration granted priority review to its new drug application for abrocitinib for the treatment of moderate-to-severe atopic dermatitis, the most common form of the inflammatory skin disease eczema, in patients 12 and older.

The New York drugmaker said the FDA is expected to make a decision in April 2021, adding that the European Medicines Agency has also accepted its application for abrocitinib in the same patient population, with a decision expected in the second half of 2021.

The FDA grants priority review to medicines that have the potential to provide significant improvements in the treatment of a serious disease, and the designation shortens the review period.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

(END) Dow Jones Newswires

October 27, 2020 07:44 ET (11:44 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Pfizer (NYSE:PFE)
Historical Stock Chart
From Oct 2020 to Nov 2020 Click Here for more Pfizer Charts.
Pfizer (NYSE:PFE)
Historical Stock Chart
From Nov 2019 to Nov 2020 Click Here for more Pfizer Charts.